Celgene Corporation (CELG)'s New Acquisition -- of Celgene
Celgene Corporation (NASDAQ:CELG) announced on Wednesday a $600 million deal to buy a stake in a growing biotech with several successful products on the market and a strong pipeline.
Exelixis Inc. (EXEL)
Market is closed
News
- First
- << Previous
- 91 - 95
5 Can't-Miss Health-Care Events This Week: Dynavax Technologies Corporation (DVAX) and More
Earnings are once again going to steal the spotlight this week, with four of the five can't-miss stories in the health-care sector revolving around earnings reports.
5 Reasons to Worry About Next Week: Exelixis, Inc. (EXEL) and More
Despite the rosy State of the Union address on Tuesday, consumers are still coping with the ramifications of the end of the payroll tax stimulus that has seen take-home pay shrink since January.
5 Can't-Miss Health-Care Events This Week: Exelixis, Inc. (EXEL), Regeneron Pharmaceuticals Inc (REGN)
With no major health-care conferences on the docket this week, and the Food and Drug Administration ruling two days early on Celgene Corporation (NASDAQ:CELG)'s multiple myeloma drug, Pomalyst, this week...
Biotech: Core and Explore - Pfizer Inc. (PFE), Merck & Co., Inc. (MRK)
Giant pharmaceutical companies are looking for the next big drug, and so are much smaller biotech outfits. Because of the methods they use, biotechs are often at the leading edge of research.
- First
- << Previous
- 91 - 95
Billionaire Hedge Funds
